Connect with us

Technology

Brainomix and Boehringer Ingelheim Advance Strategic Partnership in Pulmonary Fibrosis

Published

on

The two companies are broadening their partnership, building on strong results seen in the initial phase which demonstrated e-Lung’s potential to enable earlier diagnosis of progressive pulmonary fibrosis (PPF). Findings from the REVISE-PPF study will be presented at the American Thoracic Society (ATS) International Conference in Orlando, May 15-20, 2026.The next phase, PROGRESS-PPF, a prospective multicenter study, will focus on generating evidence of e-Lung’s clinical impact at scale, with deployments of e-Lung planned at numerous sites across the US.

OXFORD, England and CHICAGO, May 12, 2026 /PRNewswire/ — Brainomix, a global leader and pioneer of AI-powered imaging tools in lung fibrosis and stroke, today announced an expansion of its partnership with Boehringer Ingelheim, the leading biopharmaceutical company providing therapeutic options for interstitial lung disease (ILD), to improve the care of patients with progressive pulmonary fibrosis (PPF).

Patients with Interstitial Lung Diseases (ILD) may progress to PPF, a condition marked by irreversible lung damage and increased risk of early mortality. Without treatment, patients may have a lifespan as short as five years1, yet many still endure long delays – often years – before receiving a diagnosis2. Early diagnosis and intervention can play a major role in a patient’s prognosis, but determining which patients are eligible for treatment based on imaging remains challenging, even for experienced specialists.

Brainomix e-Lung is an FDA-cleared, AI-driven imaging software platform that automatically detects and quantifies abnormalities on thoracic CT scans, helping clinicians more easily identify changes, including subtle deterioration across multiple timepoints. Built on proprietary technology, e-Lung has been clinically validated to measure lung features associated with interstitial lung diseases (ILD).

Results from REVISE-PPF, a retrospective research study conducted with the University of Chicago, Weill Cornell Medical Center, and the University of Alabama at Birmingham, will be presented by Dr. Anna Podolanczuk (Weill-Cornell) at an ATS session on Sunday, May 17th. The study demonstrated that e-Lung was able to stratify patients at risk of PPF from a baseline CT and identified patients with radiologic evidence of PPF up to 28 months earlier than local clinical diagnoses.

This next phase of the Brainomix–Boehringer Ingelheim partnership aims to advance the work further, centered around a prospective, mixed-methods study, PROGRESS-PPF. Conducted across multiple sites in the US, it will generate both quantitative and qualitative real-world evidence to evaluate whether the routine use of e-Lung can support earlier clinical diagnosis of PPF, enabling treatment to begin sooner in the disease course, and, ultimately, support improved patient outcomes.

Dr. Michalis Papadakis, CEO and Co-Founder of Brainomix said: “We are excited to expand our strategic partnership with Boehringer Ingelheim, a recognized leader and innovator in this field, with whom we share a firm commitment to improving outcomes for people living with pulmonary fibrosis. The evidence generated to date for e-Lung is highly compelling, showing the technology has the potential to accelerate diagnosis by more than two years. This next phase will enable us to evaluate that potential at scale, providing robust real-world validation of what we expect could be a transformative advancement in the patient care pathway.”

“Boehringer Ingelheim is proud to expand our partnership with Brainomix as part of our continued commitment to improving care for people living with pulmonary fibrosis,” said Dr. Emmanuelle Clerisme-Beaty, Senior Vice President Medicine & Regulatory Affairs, Boehringer Ingelheim. “Progressive pulmonary fibrosis can be challenging to diagnose, and innovations that enhance our ability to detect disease have the potential to improve patient outcomes.”

An Innovation Hub session at ATS, entitled “Advancing ILD Care: Real-World Impact of Brainomix e-Lung,” will take place on Tuesday, May 19th, during which Prof. Peter George (Consultant Pulmonologist at the Royal Brompton Hospital, UK and Brainomix Senior Medical Director) will speak with Dr. Andy Limper (Mayo Clinic, Rochester) and Dr. Tathagat Narula (Mayo Clinic, Jacksonville) about their institution’s experience with Brainomix e-Lung, where it has been incorporated into routine clinical practice.

Brainomix will be exhibiting the e-Lung technology at the ATS International Conference (booth #2250) from Sunday, May 17th to Tuesday, May 19th.

About Brainomix

Brainomix is a global pioneer in AI medical imaging, enabling precision medicine for better treatment decisions in stroke and lung fibrosis. Its flagship product, Brainomix 360 Stroke, is the world’s first fully automated AI-imaging platform, designed for acute stroke assessment at all points of the patient pathway, facilitating more confident treatment and transfer decisions for patients in all hospitals, regardless of local resources or expertise. Brainomix 360 e-Lung technology applies AI-driven CT biomarkers to identify, monitor, and predict disease progression in pulmonary fibrosis. Founded as a spinout from the University of Oxford, Brainomix has offices in the UK, Ireland and the USA, and operations in more than 20 countries.

To learn more about Brainomix and its technology visit www.brainomix.com, and follow us on TwitterLinkedIn, and Facebook.

Contacts

At the company
Jeff Wyrtzen, Chief Marketing Officer
jwyrtzen@brainomix.com
T +44 (0)1865 582730

Media Enquiries
USA
Jordyn Temperato
LifeSci Communications
BrainomixMedia@lifescicomms.com

UK & Europe Media Enquiries
Sue Charles
Charles Consultants
sue@charles-consultants.com

Photo : https://mma.prnewswire.com/media/2976814/Physician__Lung_Image.jpg
Logo : https://mma.prnewswire.com/media/1989193/5963053/Brainomix_Logo.jpg

1 Khor YH et al. Patient characteristics and survival for progressive pulmonary fibrosis using different definitions. Am J Respir Crit Care Med. 2023 Jan.

2 Rajan SK et al. Progressive pulmonary fibrosis: an expert group consensus statement. Eur Respir J. 2023 Mar.

View original content to download multimedia:https://www.prnewswire.com/news-releases/brainomix-and-boehringer-ingelheim-advance-strategic-partnership-in-pulmonary-fibrosis-302768599.html

SOURCE Brainomix

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

JK Tech Brings Agentic AI to the Forefront at Two Major Industry Events

Published

on

By

NEW YORK, May 12, 2026 /CNW/ — JK Tech, a global AI and Data solutions provider has announced its participation in two premier U.S. industry forums- HFS Spring Summit and Datos Regional Property & Casualty Insurance Forum, underscoring its commitment to helping U.S. enterprises accelerate AI-led transformation with measurable business outcomes. The company will showcase how its AI-first portfolio is enabling enterprises across industries to move beyond experimentation and operationalize intelligence at scale.

As U.S. businesses grapple with growing complexity, disconnected systems, and mounting pressure to do more with less, JK Tech is stepping in with a clear message: intelligence shouldn’t sit in silos- it should be adaptable and agile.

At the HFS Spring Summit, the spotlight falls on JIVA, JK Tech’s enterprise-ready Agentic AI platform, alongside its Enterprise Ontology framework. Together, these solutions help organizations build AI systems that are contextual, governed, and explainable — not just powerful. The goal is faster decisions, modernized service delivery, and meaningful transformation across enterprise operations. Retail and commerce leaders will also get a look at Orbiee, JK Tech’s conversational commerce platform, which brings intent-aware, emotionally intelligent engagement to customer interactions, driving more personalized experiences, stronger loyalty, and better conversion outcomes.

At Datos Insights, JK Tech shifts focus to the insurance sector, showing how the same AI-led approach can help insurers modernize underwriting, claims, customer service, and core operations. The emphasis is on contextual intelligence, responsible AI, and automation that delivers real, measurable results, not just technological novelty.

Across both events, JK Tech’s core argument is consistent: the future of enterprise AI isn’t about isolated pilots. It’s about systems that work together, at scale, in the real world.

“U.S. enterprises are no longer looking for AI that simply informs, they need AI that acts,” said Deepak Srinivasan, Chief Solutions Officer at JK Tech. “We’re helping organizations move from disconnected experimentation to intelligent, outcome-driven execution by combining agentic AI, trusted enterprise data, and domain context into systems that deliver measurable business value.”

By participating in both forums, JK Tech is reinforcing its role as a reliable transformation partner for U.S. enterprises.

About JK Tech

JK Tech is a GenAI-focused data and AI services organization empowering enterprises across Retail, CPG, and Insurance. Through deep expertise in data platforms, AI orchestration, and enterprise transformation and flagship solutions such as JIVA, its Gen AI Orchestrator, and Orbiee, its conversational commerce platform, JK Tech helps global organizations unlock actionable insights, operational excellence, and sustainable growth. To learn more, visit www.jktech.com. Find JK Tech on X, LinkedIn.

Logo: https://mma.prnewswire.com/media/2088130/JK_Tech_Logo.jpg

 

View original content:https://www.prnewswire.com/news-releases/jk-tech-brings-agentic-ai-to-the-forefront-at-two-major-industry-events-302769332.html

SOURCE JK Tech

Continue Reading

Technology

Instacart Joins Collaborative for Healthy Rural America (CHRA) to Expand Access to Nutrition and Essential Goods

Published

on

By

The collaboration supports states advancing CMS Rural Health Transformation initiatives with technology-enabled implementation, AI-driven virtual primary care, and integrated access to food and community-based services

WASHINGTON, May 12, 2026 /PRNewswire/ — The Collaborative for Healthy Rural America (CHRA) today announced that Instacart has joined the collaborative, expanding its ability to help states address chronic disease and improve health outcomes by integrating access to nutritious food and essential goods into coordinated care delivery models. The addition of Instacart further enhances the collective approach to longitudinal, AI-enabled primary care and community engagement advanced by Deloitte Consulting LLP, Lumeris, Nuna, Teladoc Health, and Unite Us.

Instacart joins CHRA to help rural communities address chronic disease through better nutrition access.

The addition of Instacart comes as states begin implementing new Rural Health Transformation (RHT) initiatives with funding from the Centers for Medicare & Medicaid Services (CMS). State teams are pivoting from outlining five year plans to operationalizing and demonstrating near term progress.

“Expanding access to nutritious food is one of the most powerful things we can do to improve health outcomes,” said Sarah Mastrorocco, Vice President and General Manager of Health at Instacart. “Through Instacart Health, we’re working to use delivery of nutritious groceries as a tool to help Americans prevent and manage chronic conditions. By joining CHRA, we have an opportunity to integrate our capabilities into care delivery models further, helping states address the root causes of disease while improving access, engagement, and outcomes in rural communities.”

With approximately $10 billion in first-year RHT funding awarded nationally, states are advancing implementation within defined timelines while strengthening workforce capacity, governance structures, and performance management capabilities required under CMS cooperative agreements. As Year 2 funding decisions are informed by Year 1’s progress, states are focused on demonstrating early implementation while building durable systems designed to be sustained beyond federal funding.

The CHRA was formed to support state-directed implementation of CMS’s RHT program. CHRA brings together private sector experience and proven, interoperable technology to help states move rapidly from planning to execution. By combining advanced analytics, virtual care, interoperable data platforms, and closed-loop referrals for community-based service integration, CHRA enables states to operationalize complex rural health transformation initiatives at scale, reducing the need for each state to build new capabilities from scratch.

CHRA’s founding collaborators include Deloitte, Lumeris, Nuna, Teladoc Health, and Unite Us. The addition of Instacart to the collaborative helps states expand access to nutritious foods and everyday essentials to address chronic disease and related needs. Together, CHRA represents a comprehensive operating model that is intentionally aligned with CMS expectations, reducing the need for health systems to assemble and manage disparate components independently

Built Around State-Identified Challenges

CHRA conducted a detailed review of publicly available state RHT plans to understand the challenges states themselves have identified as most urgent. While needs vary by geography, four themes consistently emerged across plans.

1. Infrastructure Misalignment in Rural Health Systems

States across the country describe a structural mismatch between legacy rural health infrastructure, declining populations, and fee-for-service payment models. The State of Wyoming notes that rural hospitals face “high fixed costs and low patient volume,” while still needing to maintain emergency capacity. Vermont reports that more than half of hospitals operate at a loss due to low volume, workforce shortages, aging infrastructure, and high fixed operating costs. Illinois highlights large inpatient facilities that are rarely fully occupied, undermining financial viability. Across the country, rural health transformation plans converge on the need for alternative payment models, redesigned delivery systems, flexible workforce strategies, and technology-enabled care to create sustainable models of care.

How CHRA can help states:
CHRA supports states in exploring and operationalizing redesigned care delivery models better suited to low volume, high fixed cost environments such as those intended to be addressed by RHT initiatives. At the core of this approach is the transformation of primary care from episodic, site-based care to continuous, coordinated, and population-driven models that better meet the needs of rural communities.

Through interoperable service models, built to complement existing EHR and HIE systems, CHRA has the opportunity to support beneficiary identification, outreach, virtual and in-person care, care coordination, and outcomes tracking. For instance, CHRA member Lumeris, powered by Tom™, enables primary care teams to operate with greater reach and efficiency—proactively managing patient populations, closing care gaps, and extending care beyond traditional settings.

These supports, alongside virtual care delivery through Teladoc Health’s network of providers and Nuna’s AI-native patient engagement mobile app, introduce a more scalable, prevention-oriented primary care model that aligns payment, workforce capacity, and service delivery with population needs while relieving rural facilities of the burden of sustaining underutilized infrastructure on their own.

2. Gaps in Preventive Care Delivery

States report persistent barriers to preventive services. The State of Iowa cites gaps in early detection and prevention. The State of Maine highlights limited capacity for population-level screening and outreach. Workforce shortages, transportation challenges, and infrastructure constraints limit consistent access to preventive care.

How CHRA can help states:
CHRA leverages population data, predictive analytics, and AI-supported outreach to help states identify priority populations and close preventive care gaps. Unite Us’ Self Sufficiency Score establishes a benchmark, connecting rural residents to medical, behavioral, and community support services via an integrated closed-loop referral and payment platform.

Utilizing the Tom™ platform, CHRA extends prevention beyond episodic care by continuously monitoring patient needs, proactively identifying rising risks, and engaging individuals between visits through timely, personalized outreach. By orchestrating interventions across care teams and community resources, Tom helps ensure preventive actions happen earlier, before conditions escalate, enabling more consistent care, improving health outcomes, and reducing downstream costs associated with avoidable complications.

3. High Burden of Chronic Disease

Chronic disease management is a central concern across state plans. The State of Nevada identifies heart disease, cancer, and chronic lower respiratory disease as leading causes of death. The State of New Jersey emphasizes the need to modernize identification and access to treatment. The State of New Mexico calls for expanded specialty access and evidence-based models, while the Commonwealth of Virginia highlights access to nutrition as a root cause of poor health.

How CHRA can help states:
CHRA helps states more effectively prevent and slow chronic disease by enabling continuous, data-driven management of patient populations. Tom identifies rising-risk individuals, closes care gaps, and proactively engages patients between visits—supporting adherence, surfacing unmet needs, and coordinating timely interventions across care teams. Through CHRA, partners like Teladoc Health that integrate Instacart Health tools, will extend this model by enabling interventions that deliver personalized, clinically aligned nutrition support directly to patients, addressing key drivers of chronic conditions. Using Instacart Health Fresh Funds, stipends for nutritious food, and Care Carts, which allow organizations to order groceries on behalf of others, partners can build programs that address the needs of rural communities. Together, this approach tackles root causes, improves long-term disease management, and reduces avoidable emergency utilization.

4. Workforce Shortages and Provider Access

States consistently cite challenges with recruiting and retaining providers. The State of Ohio reports service lines at risk due to workforce shortages. The State of Nevada ranks near the bottom nationally in physician availability. The State of Georgia reports that most counties are facing a shortage of OBGYNs or pediatricians. Nationally, more than 190 rural hospitals have closed since 2005, with hundreds more at risk, according to the North Carolina Rural Health Research Program.

How CHRA can help states:
CHRA supports Primary Care as a Service (PCaaS) models using solutions like Lumeris’ Tom™ platform, which provides the backbone technology that extends provider capacity through AI-assisted triage, virtual care, and team-based workflows. Deloitte provides cross-platform interoperability and data integration services, grounded in decades of experience supporting states. And Teladoc Health has the largest nationwide network of virtual care providers including licensed clinicians, therapists, and health coaches, and can help patients access care quickly amid shortages or barriers to care. These approaches aim to expand access while keeping local providers at the center of care and reducing burnout. 

Looking Ahead

States will report Year 1 progress to CMS in October 2026. Those that demonstrate measurable improvements in access, utilization, and sustainability will be positioned for continued funding. CHRA’s role is to support states in achieving early momentum while building sustainable rural health systems.

About CHRA

The Collaborative for Healthy Rural America (CHRA) is a coalition of organizations supporting state led rural health transformation initiatives through coordinated, implementation focused support across care delivery, data, community integration, and sustainability.

Learn more: https://healthyruralamerica.org

View original content:https://www.prnewswire.com/news-releases/instacart-joins-collaborative-for-healthy-rural-america-chra-to-expand-access-to-nutrition-and-essential-goods-302768800.html

SOURCE Lumeris

Continue Reading

Technology

Branford Castle-Backed Lafayette Instrument Acquires Sutter Instrument Corp.

Published

on

By

Significantly Expands Its Life Sciences Instrumentation Product Offerings

NEW YORK and BOCA RATON, Fla., May 12, 2026 /PRNewswire/ — Lafayette Instrument, LLC, a leading global manufacturer of scientific instrumentation equipment for the life sciences, polygraph and human evaluation markets, today announced that it has acquired Sutter Instrument Corp. Terms of the transaction were not disclosed.

Lafayette is a portfolio company of North American-focused private equity firm Branford Castle Partners. Sutter marks the fifth bolt-on investment for Lafayette since being acquired by Branford Castle’s Fund II in 2021.

With the acquisition of Sutter, Lafayette reinforces its commitment to provide unparalleled support to the life science research community through experiment-focused software and instrumentation. Sutter is a leading provider of precision scientific instruments used by universities and research institutions globally for electrophysiology, neuroscience, and other related life sciences research.

Benjamin Mangrich, CEO of Lafayette Instrument, said, “Sutter Instrument has been a global leader in instrumentation supporting cellular research and electrophysiology for over 50 years. The company’s strong product portfolio, deep technical expertise, and commitment to customer success make them a natural complement to Lafayette Instrument’s Life Science portfolio.”

Ceon Francis, Managing Director at Branford Castle, stated, “This acquisition strengthens Lafayette’s platform and broadens its product offering to better serve a growing base of life sciences customers who demand the latest tools and technology. We are excited to collaborate with management as we continue to build on the company’s momentum and drive long-term growth.”

Branford Castle was advised by its legal counsel Akerman LLP, and RSM served as its accounting/tax advisor. EC M&A acted as financial advisor and Donahue Fitzgerald LLP acted as legal advisor to Sutter. Byline Bank is providing senior debt financing and Brookside Capital Partners is providing mezzanine debt financing for the transaction.

ABOUT BRANFORD CASTLE PARTNERS
Branford Castle is a private market investor focused on lower middle-market investments, with more than 35 years of helping to grow businesses. The Firm typically makes control investments in companies with up to $15 million of EBITDA and a leadership position in a niche industry. Branford Castle prides itself on the strong relationships it develops with its portfolio company managers. Branford Castle has particular expertise in industrials/specialty manufacturing, consumer products, business services and logistics.

ABOUT LAFAYETTE INSTRUMENT
Lafayette Instrument Company has over 75 years of experience engineering and manufacturing high-quality scientific instrumentation and data acquisition equipment for disciplines such as biology, neuroscience, pharmaceutical and medical research, physical therapy and rehabilitation, security, and law enforcement. Lafayette is positioned at the forefront of neuroscientific discovery, human evaluation, and credibility assessment.

Media Contact:
LLYC
Jennifer Hurson
Jennifer.hurson@llyc.global
Or
Joanne Lessner
Joanne.lessner@llyc.global

 

View original content:https://www.prnewswire.com/news-releases/branford-castle-backed-lafayette-instrument-acquires-sutter-instrument-corp-302769068.html

SOURCE Branford Castle Partners

Continue Reading

Trending